181 related articles for article (PubMed ID: 27527851)
1. Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells.
Lin CY; Chao A; Wang TH; Lee LY; Yang LY; Tsai CL; Wang HS; Lai CH
Oncotarget; 2016 Sep; 7(37):60038-60052. PubMed ID: 27527851
[TBL] [Abstract][Full Text] [Related]
2. Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23).
Chao A; Lin CY; Tsai CL; Hsueh S; Lin YY; Lin CT; Chou HH; Wang TH; Lai CH; Wang HS
J Mol Med (Berl); 2013 Feb; 91(2):249-59. PubMed ID: 22926011
[TBL] [Abstract][Full Text] [Related]
3. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.
Woodfield GW; Horan AD; Chen Y; Weigel RJ
Cancer Res; 2007 Sep; 67(18):8439-43. PubMed ID: 17875680
[TBL] [Abstract][Full Text] [Related]
4. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells.
Velarde MC; Zeng Z; McQuown JR; Simmen FA; Simmen RC
Mol Endocrinol; 2007 Dec; 21(12):2988-3001. PubMed ID: 17717078
[TBL] [Abstract][Full Text] [Related]
5. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
6. Roles of estrogen receptor α and β in the regulation of proliferation in endometrial carcinoma.
Hu G; Zhang J; Zhou X; Liu J; Wang Q; Zhang B
Pathol Res Pract; 2020 Oct; 216(10):153149. PubMed ID: 32853964
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1.
Kang HJ; Lee MH; Kang HL; Kim SH; Ahn JR; Na H; Na TY; Kim YN; Seong JK; Lee MO
Cancer Res; 2014 Mar; 74(5):1484-94. PubMed ID: 24413532
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of peroxisome proliferator-activated receptor γ inhibits estrogen receptor α transcriptional activity in endometrial carcinoma cells.
Zhang G; Hou X; Gao S
Oncol Rep; 2015 Mar; 33(3):1227-34. PubMed ID: 25592200
[TBL] [Abstract][Full Text] [Related]
9. TFAP2C regulates carbonic anhydrase XII in human breast cancer.
Franke CM; Gu VW; Grimm BG; Cassady VC; White JR; Weigel RJ; Kulak MV
Oncogene; 2020 Feb; 39(6):1290-1301. PubMed ID: 31636386
[TBL] [Abstract][Full Text] [Related]
10. Histone acetyltransferase MOF is involved in suppression of endometrial cancer and maintenance of ERα stability.
Wu Y; Zeng K; Wang C; Wang S; Sun H; Liu W; Wang X; Niu J; Cong SY; Zhou X; Zhao Y
Biochem Biophys Res Commun; 2019 Feb; 509(2):541-548. PubMed ID: 30598260
[TBL] [Abstract][Full Text] [Related]
11. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth.
Lin CY; Lee LY; Wang TH; Hsu CL; Tsai CL; Chao A; Lai CH
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31330844
[TBL] [Abstract][Full Text] [Related]
14. A20-mediated deubiquitination of ERα in the microenvironment of CD163
Lv Q; Xie L; Cheng Y; Shi Y; Shan W; Ning C; Xie B; Yang B; Luo X; He Q; Zhu Q; Zhang Y; Zhang Z; Wang C; Chen X; Xu C
Cancer Lett; 2019 Feb; 442():137-147. PubMed ID: 30420335
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Claudin-6-Adhesion Signaling Promotes Endometrial Cancer Progression via Estrogen Receptor α.
Kojima M; Sugimoto K; Kobayashi M; Ichikawa-Tomikawa N; Kashiwagi K; Watanabe T; Soeda S; Fujimori K; Chiba H
Mol Cancer Res; 2021 Jul; 19(7):1208-1220. PubMed ID: 33727343
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
17. CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer.
Padmanabhan RA; Nirmala L; Murali M; Laloraya M
Mol Endocrinol; 2011 Sep; 25(9):1499-512. PubMed ID: 21700719
[TBL] [Abstract][Full Text] [Related]
18. The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells.
Bryant W; Snowhite AE; Rice LW; Shupnik MA
Endocrinology; 2005 Feb; 146(2):751-9. PubMed ID: 15528307
[TBL] [Abstract][Full Text] [Related]
19. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
20. [Study on the modulation of estrogen receptor isoforms alpha in endometrial carcinoma cells using antisense oligodeoxyribonucleotides].
Zhang Y; Liao QP; Yu L; Chen CL; Zhao J
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 37(2):155-8. PubMed ID: 15841144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
